Erli Zhang
Pfizer (United States)(US)
Publications by Year
Research Areas
Blood Coagulation and Thrombosis Mechanisms, Renin-Angiotensin System Studies, Receptor Mechanisms and Signaling, Melanoma and MAPK Pathways, Coagulation, Bradykinin, Polyphosphates, and Angioedema
Most-Cited Works
- → Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition(2004)614 cited
- → Pyrido[2,3-d]pyrimidin-7-one Inhibitors of Cyclin-Dependent Kinases(2000)153 cited
- → 2-Alkylamino- and alkoxy-substituted 2-amino-1,3,4-oxadiazoles—O-Alkyl benzohydroxamate esters replacements retain the desired inhibition and selectivity against MEK (MAP ERK kinase)(2008)67 cited
- → Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors(2007)52 cited
- → Binding thermodynamics of substituted diaminopyrimidine renin inhibitors(2006)41 cited
- → The Discovery of (2R,4R)‐N‐(4‐chlorophenyl)‐N‐ (2‐fluoro‐4‐(2‐oxopyridin‐1(2H)‐yl)phenyl)‐4‐methoxypyrrolidine‐1,2‐dicarboxamide (PD 0348292), an Orally Efficacious Factor Xa Inhibitor(2007)39 cited
- → Ketopiperazine-based renin inhibitors: Optimization of the “C” ring(2006)37 cited
- → Potent and Selective Thrombin Inhibitors Incorporating the Constrained Arginine Mimic l-3-Piperidyl(N-guanidino)alanine at P1(1996)31 cited
- → The discovery of fluoropyridine-based inhibitors of the Factor VIIa/TF complex(2005)30 cited
- → Discovery of 6-ethyl-2,4-diaminopyrimidine-based small molecule renin inhibitors(2007)29 cited